147 filings
8-K
ONCSQ
ONCOSEC MEDICAL Inc
22 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
ONCSQ
ONCOSEC MEDICAL Inc
14 Jun 23
Bankruptcy or Receivership
5:20pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
14 Jun 23
Departure of Directors or Certain Officers
4:55pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
2 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
18 May 23
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:35pm
8-K
dskrb7 ehbdl7oa0niu
16 May 23
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
8:15am
8-K
f13si6vlrkwr
27 Apr 23
Other Events
8:00am
8-K
fmhn 7vvomd2yrm
11 Apr 23
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:05pm
8-K
pfsi2we 1t6uoqkj
3 Apr 23
Other Events
7:30am
8-K
oye1z 547
22 Feb 23
Other Events
8:30am
8-K
hqy8t18mh
4 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:10pm
8-K
r9f045
28 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
q5x2wk7
27 Dec 22
Departure of Directors or Certain Officers
5:00pm
8-K
9bayd7eh 8m6c
1 Dec 22
OncoSec Announces Pricing of $3.5 Million Public Offering
4:57pm
8-K
8ja5z7
29 Nov 22
Entry into a Material Definitive Agreement
8:00am
8-K
67d2squ3ivomsci
22 Nov 22
Other Events
5:00pm
8-K
ry4y0tgitcx61 sf7
15 Nov 22
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
5:06pm
8-K
970 qa2kg9b6hmxdxa
14 Nov 22
Other Events
6:10am
8-K
qy658j4
8 Nov 22
OncoSec Announces Reverse Stock Split
1:15pm
8-K
438digzmid4uq6e6te
17 Oct 22
Departure of Directors or Certain Officers
5:00pm